Increased fibroblast growth factor-21 in chronic kidney disease is a trade-off between survival benefit and blood pressure dysregulation.

ABSTRACT: Circulating levels of fibroblast growth factor-21 (FGF21) start increasing in patients with chronic kidney disease (CKD) since early stages during the cause of disease progression. FGF21 is a liver-derived hormone that induces responses to stress through acting on hypothalamus to activate the sympathetic nervous system and the hypothalamus-pituitary-adrenal endocrine axis. However, roles that FGF21 plays in pathophysiology of CKD remains elusive. Here we show in mice that FGF21 is required to survive CKD but responsible for blood pressure dysregulation. When introduced with CKD, Fgf21^-/- mice died earlier than wild-type mice. Paradoxically, these Fgf21^-/- CKD mice escaped several complications observed in wild-type mice, including augmentation of blood pressure elevat

SUBMITTER: Nakano T 

PROVIDER: S-EPMC6917750 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature